115 related articles for article (PubMed ID: 12814959)
21. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
[TBL] [Abstract][Full Text] [Related]
22. Effect of glutathione on the covalent binding of the 13C-labeled skin sensitizer 5-chloro-2-methylisothiazol-3-one to human serum albumin: identification of adducts by nuclear magnetic resonance, matrix-assisted laser desorption/ionization mass spectrometry, and nanoelectrospray tandem mass spectrometry.
Alvarez-Sánchez R; Divkovic M; Basketter D; Pease C; Panico M; Dell A; Morris H; Lepoittevin JP
Chem Res Toxicol; 2004 Sep; 17(9):1280-8. PubMed ID: 15377163
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
24. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
[TBL] [Abstract][Full Text] [Related]
25. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
Prakash C; Wang W; O'Connell T; Johnson KA
Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
[TBL] [Abstract][Full Text] [Related]
26. In vitro metabolic activation of thiabendazole via 5-hydroxythiabendazole: identification of a glutathione conjugate of 5-hydroxythiabendazole.
Dalvie D; Smith E; Deese A; Bowlin S
Drug Metab Dispos; 2006 Apr; 34(4):709-17. PubMed ID: 16434547
[TBL] [Abstract][Full Text] [Related]
27. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
28. The covalent binding of [14C]acetaminophen to mouse hepatic microsomal proteins: the specific binding to calreticulin and the two forms of the thiol:protein disulfide oxidoreductases.
Zhou L; McKenzie BA; Eccleston ED; Srivastava SP; Chen N; Erickson RR; Holtzman JL
Chem Res Toxicol; 1996; 9(7):1176-82. PubMed ID: 8902274
[TBL] [Abstract][Full Text] [Related]
29. Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA.
Fan PW; Bolton JL
Drug Metab Dispos; 2001 Jun; 29(6):891-6. PubMed ID: 11353759
[TBL] [Abstract][Full Text] [Related]
30. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.
Singh R; Silva Elipe MV; Pearson PG; Arison BH; Wong BK; White R; Yu X; Burgey CS; Lin JH; Baillie TA
Chem Res Toxicol; 2003 Feb; 16(2):198-207. PubMed ID: 12588191
[TBL] [Abstract][Full Text] [Related]
31. Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine.
Ames MM; Sanders ME; Tiede WS
Cancer Res; 1983 Feb; 43(2):500-4. PubMed ID: 6401219
[TBL] [Abstract][Full Text] [Related]
32. Modifications in the low mobility group nuclear proteins by reactive metabolites of diethylstilbestrol.
Roy D; Pathak DN
Biochem Mol Biol Int; 1993 Dec; 31(5):923-34. PubMed ID: 8136710
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
[TBL] [Abstract][Full Text] [Related]
34. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
Masubuchi N; Makino C; Murayama N
Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
[TBL] [Abstract][Full Text] [Related]
35. Saturation toxicokinetics of thioacetamide: role in initiation of liver injury.
Chilakapati J; Shankar K; Korrapati MC; Hill RA; Mehendale HM
Drug Metab Dispos; 2005 Dec; 33(12):1877-85. PubMed ID: 16183780
[TBL] [Abstract][Full Text] [Related]
36. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore.
Williams DP; Antoine DJ; Butler PJ; Jones R; Randle L; Payne A; Howard M; Gardner I; Blagg J; Park BK
J Pharmacol Exp Ther; 2007 Sep; 322(3):1208-20. PubMed ID: 17556636
[TBL] [Abstract][Full Text] [Related]
37. Determination of a neuroprotective agent (S)-(+)-BMS-204352 in human, rat and dog plasma by enantioselective liquid chromatography-tandem mass spectrometry.
Zeng J; Palme H; Srinivas N; Arnold M
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Nov; 811(2):109-17. PubMed ID: 15522709
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 3-azidiamantane as photoaffinity probe of cytochrome P450.
Hodek P; Smrcek S
Gen Physiol Biophys; 1999 Jun; 18(2):181-98. PubMed ID: 10517292
[TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
40. In vitro system to estimate renal brush border enzyme-mediated cleavage of Peptide linkages for designing radiolabeled antibody fragments of low renal radioactivity levels.
Fujioka Y; Satake S; Uehara T; Mukai T; Akizawa H; Ogawa K; Saji H; Endo K; Arano Y
Bioconjug Chem; 2005; 16(6):1610-6. PubMed ID: 16287261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
